TY - JOUR
T1 - Ocular neovascularisation and excessive vascular permeability
AU - Campochiaro, Peter A.
N1 - Funding Information:
Supported by grants EY05951, EY10017, EY09769, EY11279 and core grant P30EY1765 from the National Eye Institute, the Macula Vision Foundation, a Lew R. Wasserman Merit Award and unrestricted funds from Research to Prevent Blindness, and a grant from Dr and Mrs W Lake. The author is the George S. and Dolores Dore Eccles Professor of Ophthalmology and Neuroscience.
PY - 2004/9
Y1 - 2004/9
N2 - Diseases complicated by vascular leakage and/or neovascularisation in the eye are responsible for the vast majority of visual morbidity and blindness in developed countries. The molecular signals that control vascular permeability and neovascularisation in the eye are being defined. Members of the vascular endothelial growth factor (VEGF) family are key stimulators that interact with two tyrosine kinase receptors, VEGF receptor (VEGFR)1 and 2; binding to two other receptors that lack tyrosine kinase activity, the neuropilins, is also important. Signalling through the VEGF pathway is modulated by the Tie2 receptor and its binding partners, the angiopoietins. Each of the participants in these two signalling pathways provides a potential target for intervention. Several proteins with antiangiogenic activity balance the stimulators and the outcome is determined by the net balance. Endostatin suppresses vascular permeability as well as ocular neovascularisation, suggesting that vascular leakage may also be regulated by counteracting proteins. Gene transfer provides a useful way to influence these balances. Clinical trials are underway to test whether these mechanisms can be translated into new therapies.
AB - Diseases complicated by vascular leakage and/or neovascularisation in the eye are responsible for the vast majority of visual morbidity and blindness in developed countries. The molecular signals that control vascular permeability and neovascularisation in the eye are being defined. Members of the vascular endothelial growth factor (VEGF) family are key stimulators that interact with two tyrosine kinase receptors, VEGF receptor (VEGFR)1 and 2; binding to two other receptors that lack tyrosine kinase activity, the neuropilins, is also important. Signalling through the VEGF pathway is modulated by the Tie2 receptor and its binding partners, the angiopoietins. Each of the participants in these two signalling pathways provides a potential target for intervention. Several proteins with antiangiogenic activity balance the stimulators and the outcome is determined by the net balance. Endostatin suppresses vascular permeability as well as ocular neovascularisation, suggesting that vascular leakage may also be regulated by counteracting proteins. Gene transfer provides a useful way to influence these balances. Clinical trials are underway to test whether these mechanisms can be translated into new therapies.
KW - Age-related macular degeneration
KW - Angiogenesis
KW - Diabetic retinopathy
KW - Macular oedema
KW - Neovascularisation
KW - Proliferarive retinopathies
UR - http://www.scopus.com/inward/record.url?scp=4544333728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4544333728&partnerID=8YFLogxK
U2 - 10.1517/14712598.4.9.1395
DO - 10.1517/14712598.4.9.1395
M3 - Review article
C2 - 15335307
AN - SCOPUS:4544333728
SN - 1471-2598
VL - 4
SP - 1395
EP - 1402
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
IS - 9
ER -